These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16804994)

  • 21. Overcoming the Next Barriers to Successful Therapy.
    Cohen IJ; Baris H; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
    [No Abstract]   [Full Text] [Related]  

  • 22. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases.
    Sánchez-Fernández EM; García Fernández JM; Mellet CO
    Chem Commun (Camb); 2016 Apr; 52(32):5497-515. PubMed ID: 27043200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein structural features predict responsiveness to pharmacological chaperone treatment for three lysosomal storage disorders.
    Woodard J; Zheng W; Zhang Y
    PLoS Comput Biol; 2021 Sep; 17(9):e1009370. PubMed ID: 34529671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies.
    Brady RO
    Acta Paediatr Suppl; 2003 Dec; 92(443):19-24. PubMed ID: 14989461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of Gaucher disease: enzyme replacement therapy and emerging therapies (chemical chaperone and gene therapy)].
    Grosbois B; Revest M; Decaux O; Sebillot M
    Ann Biol Clin (Paris); 2006; 64(6):600-2. PubMed ID: 17256241
    [No Abstract]   [Full Text] [Related]  

  • 27. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
    Fabrega S; Lehn P
    J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rheumatologic aspects of lysosomal storage diseases.
    Manger B; Mengel E; Schaefer RM
    Clin Rheumatol; 2007 Mar; 26(3):335-41. PubMed ID: 16680390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement with red cells.
    N Engl J Med; 1977 Apr; 296(16):942-3. PubMed ID: 846521
    [No Abstract]   [Full Text] [Related]  

  • 30. Advances in the treatment of inherited metabolic diseases.
    Desnick RJ; Grabowski GA
    Adv Hum Genet; 1981; 11():281-369. PubMed ID: 6115548
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of fabry disease: current and emerging strategies.
    Rozenfeld P; Neumann PM
    Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genzyme resumes shipping as Sanofi-aventis hovers.
    Ratner M
    Nat Biotechnol; 2010 Oct; 28(10):994. PubMed ID: 20944572
    [No Abstract]   [Full Text] [Related]  

  • 33. Therapy for Gaucher disease: don't stop thinking about tomorrow.
    Sidransky E; LaMarca ME; Ginns EI
    Mol Genet Metab; 2007 Feb; 90(2):122-5. PubMed ID: 17084653
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enzyme Replacement Therapy in a Gaucher Family.
    Erdem N; Buran T; Berber I; Aydogdu I
    J Natl Med Assoc; 2018 Aug; 110(4):330-333. PubMed ID: 30126557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
    Suzuki Y
    Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fabry disease: kidney transplantation as an enzyme replacement technic.
    Philippart M
    Birth Defects Orig Artic Ser; 1973 Mar; 9(2):81-7. PubMed ID: 4215478
    [No Abstract]   [Full Text] [Related]  

  • 37. Enzyme replacement therapy for Fabry disease: proving the clinical benefit.
    Breunig F; Wanner C
    Nephrol Dial Transplant; 2003 Jan; 18(1):7-9. PubMed ID: 12480950
    [No Abstract]   [Full Text] [Related]  

  • 38. The role of neurogenetics in Gaucher disease.
    Brady RO; Barton NW; Grabowski GA
    Arch Neurol; 1993 Nov; 50(11):1212-24. PubMed ID: 8215980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel therapeutic targets for the treatment of Fabry disease.
    Hollak CE; Vedder AC; Linthorst GE; Aerts JM
    Expert Opin Ther Targets; 2007 Jun; 11(6):821-33. PubMed ID: 17504019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of antibodies in enzyme treatments and therapeutic strategies.
    Bigger BW; Saif M; Linthorst GE
    Best Pract Res Clin Endocrinol Metab; 2015 Mar; 29(2):183-94. PubMed ID: 25987172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.